-
ARE POST-LAUNCH DATA FROM RARE DISEASE REGISTRIES FIT FOR HTA POLICY DECISIONS? LESSONS FROM THE DUTCH CYSTIC FIBROSIS REGISTRY
Aug 11, 2026, 17:16 PM -
BAYESIAN LATENT CLASS MODELS FOR VALIDATING PHENOTYPING ALGORITHMS IN MEDICO-ADMINISTRATIVE DATABASES: A SYSTEMATIC REVIEW WITH FOCUS ON CASE-ONLY GOLD STANDARDS
Aug 11, 2026, 17:16 PM -
IMPACT OF 2022 LEGISLATIVE CHANGES ON ORPHAN MEDICINAL PRODUCTS REIMBURSEMENT IN THE CZECH REPUBLIC
Aug 11, 2026, 17:16 PM -
HEALTH TECHNOLOGY ASSESSMENT OF MIDFACE THREAD LIFTING: A SYSTEMATIC REVIEW OF COMPLICATION RATES AND A NOVEL SAFETY GRADING SYSTEM
Aug 11, 2026, 17:16 PM -
REASSESSING ORPHAN DRUGS: EFFECTS OF THE €30 MILLION THRESHOLD ON ADDED BENEFIT AND PRICING IN GERMANY
Aug 11, 2026, 17:16 PM -
GENDER DIFFERENCES IN FIRST-TIME ADMITTED OPIOID USERS RECEIVING MEDICATION FOR OPIOID USE DISORDER (MOUD)
Aug 11, 2026, 17:16 PM -
RESPONSIBLE AI-ENABLED HEALTH TECHNOLOGY ASSESSMENT (HTA) IN MENA: A QUALITATIVE EXPERT-CONSENSUS ROADMAP
Aug 11, 2026, 17:16 PM -
CONFOUNDING AND ADJUSTMENT CONCERNS IN EXTERNAL CONTROL ARM EVIDENCE SUBMITTED TO IQWIG
Aug 11, 2026, 17:16 PM -
THE COST OF DIABETES CARE: HEALTHCARE SPENDING AND TREATMENT UTILIZATION AMONG DAMAN BENEFICIARIES IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
THE ECONOMIC VALUE OF INVESTING IN ADDICTION PSYCHIATRY: A HEALTH POLICY PERSPECTIVE FROM POLAND
Aug 11, 2026, 17:16 PM -
TRENDS IN OBESITY INCIDENCE, PREVALENCE AND GLP-1 RECEPTOR AGONIST PRESCRIBING IN THE UK: EVIDENCE FROM A REAL-WORLD PRIMARY CARE COHORT
Aug 11, 2026, 17:16 PM -
BUDGET AND ENVIRONMENTAL IMPACT ANALYSIS OF MULTI-LAYER WATERTIGHT CLOSURE VERSUS CONVENTIONAL CLOSURE IN TOTAL JOINT ARTHROPLASTY IN UK
Aug 11, 2026, 17:16 PM -
BEHAVIORAL STEWARDSHIP TO OPTIMIZE ICU ANTIBIOTIC USE IN RESOURCE-LIMITED SETTINGS
Aug 11, 2026, 17:16 PM -
BEYOND ICD CODES: USING PATHOLOGY DATA TO IDENTIFY BIOMARKER-DEFINED COHORTS AND CLINICALLY MEANINGFUL SUBGROUPS IN REAL-WORLD DATA
Aug 11, 2026, 17:16 PM -
A REAL-WORLD COST-EFFECTIVENESS ANALYSIS USING TWO HOSPITAL SETTINGS ON REAL-WORLD DOSING OF PEMBROLIZUMAB IN ADVANCED NSCLC
Aug 11, 2026, 17:16 PM -
RARE DISEASE, SIGNIFICANT BURDEN: UNMET MEDICAL NEED AND EPIDEMIOLOGY OF IDH-MUTANT GRADE 2 GLIOMA IN PORTUGAL
Aug 11, 2026, 17:16 PM -
TIME FOR A CORE OUTCOMES SET? A FOCUS ONDISEASE MODIFYING THERAPIES FOR EARLY ALZHEIMER'S DISEASE
Aug 11, 2026, 17:16 PM -
DO TRUMPRX PRICES MATCH THE LOWEST PRICES IN EUROPE? A CROSS-COUNTRY COMPARISON
Aug 11, 2026, 17:16 PM -
THE ECONOMIC BURDEN OF FRIEDREICH ATAXIA IN LATIN AMERICA: RESULTS OF AN ONLINE PATIENT AND CAREGIVER SURVEY
Aug 11, 2026, 17:16 PM -
WHO IS A CAREGIVER? A TARGETED REVIEW OF ELIGIBILITY CRITERIA IN QUALITATIVE RESEARCH WITH CAREGIVERS
Aug 11, 2026, 17:16 PM
